Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol

Executive Summary

Commissioner Gottlieb announces several actions in the works to promote development of new treatments for opioid addiction, including guidance on how to establish novel endpoints.

Advertisement

Related Content

Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
FDA's Kratom Campaign Turns To Firms Destroying Inventory, Recalling Products
BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking
Opioid Litigation: Court Asks US FDA To Attend Education Session
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control
Opioid Packaging Changes Might Deter Abuse – And Generic Competition
Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says
US FDA May Change Opioid Labeling To Limit Dispensing By Indication

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel